CVS Health Corporation research snapshot
CVS AI stock analysis currently reads CVS Health as a recovering integrated health care platform with pharmacy retail, Caremark PBM, Aetna insurance, and care delivery assets. At the July 8, 2026 data cutoff, CVS traded near $104.33 after a large 52-week recovery, while Q1 2026 revenue grew 6.2% to $100.4 billion and management raised full-year adjusted EPS guidance to $7.30 to $7.50. The CVS AI stock forecast is scenario-based, not a precise prediction, because the investment case depends on Aetna medical cost execution, PBM regulation, pharmacy reimbursement pressure, Oak Street and care delivery discipline, debt reduction, and whether the market values CVS on recovered adjusted earnings or still-disrupted GAAP earnings.
Current price
$104.33
Market cap
$133.12 billion verified market cap
AI score
66 / 100
Rating
Improving health care turnaround with strong revenue scale, high leverage, and policy-sensitive earnings risk
Trend status
Constructive but extended, above both the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CVS sells pharmacy access, prescription benefit management, health insurance, retail health services, and care coordination to members, employers, plans, and patients at national scale. | High |
| Moat | Scale, pharmacy density, Caremark claims data, Aetna membership, specialty pharmacy capabilities, employer relationships, and integrated benefit design create switching costs, but policy pressure can narrow the moat. | Medium-high |
| Management | David Joyner is executing a margin recovery and simplification plan after a difficult 2024 and 2025 period, with credibility improving but still tied to medical cost control and care delivery discipline. | Medium |
| Financial trend | FY2025 total revenues rose 7.8% to $402.1 billion, adjusted operating income rose 20.6% to $14.4 billion, but GAAP net income attributable to CVS Health fell to $1.77 billion after impairment and litigation charges. | High |
| Valuation | At $104.33, CVS screens near 45.36x TTM EPS, 13.68x forward earnings, 1.71x book value, 17.99x free cash flow per share, and a 2.55% dividend yield. | High |
| Technical trend | CVS is above the 50-day moving average near $94.44 and the 200-day average near $81.87, with RSI near 64.20 and the price close to its 52-week high. | Medium |
| Risk level | Main risks are elevated medical costs, Medicare Advantage margin pressure, PBM regulation, pharmacy reimbursement pressure, debt, store footprint changes, care delivery execution, and political scrutiny. | Medium-high |
| AI confidence | Descriptive confidence is high because company filings and StockAnalysis data align on the major facts. Forecast confidence is lower because policy and medical cost trend are hard to model. | High data confidence |
| Investment certainty | CVS has a credible turnaround, but after the rally the setup needs continued guidance execution rather than just a low historical multiple story. | Medium |
CVS AI stock forecast
The CVS AI stock forecast uses the $104.33 price reference, TTM EPS of $2.30, management guidance for 2026 adjusted EPS of $7.30 to $7.50, and a three-year scenario model. The mechanical GAAP EPS model produced conservative targets near $18 in a bear case, $38 in a base case, and $56 in a bullish case because current GAAP EPS remains depressed. A more useful investor range must therefore anchor on whether adjusted EPS recovers and converts to cash without new impairments or policy shocks.
$115 to $135
More likely if CVS delivers raised 2026 adjusted EPS guidance, Health Care Benefits margins keep recovering, cash flow stays above $9.5 billion, debt falls, and investors assign a mid-teens multiple to sustainable adjusted EPS.
$95 to $115
More likely if revenue grows in the low to mid single digits, adjusted EPS improves but GAAP earnings remain noisy, and the market values CVS near its analyst target range while waiting for cleaner Aetna and care delivery results.
$70 to $90
More likely if medical cost trend rises, PBM economics are reset, pharmacy reimbursement pressure offsets volume, Oak Street or other care assets need more charges, or debt limits shareholder returns.
CVS AI technical analysis
CVS AI technical analysis is constructive but extended as of the July 8, 2026 cutoff. StockAnalysis showed a July 7 close of $104.33, a 50-day moving average near $94.44, a 200-day moving average near $81.87, RSI near 64.20, 20-day average volume near 7.99 million shares, and a 52-week range of $58.50 to $106.15. The chart has trend support, but the risk-reward is less obvious near the top of the one-year range.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $104.33 | StockAnalysis listed the July 7, 2026 close at $104.33 and pre-market trading near $103.93 on July 8. |
| Immediate support | $100 to $102 | This zone brackets the prior close area and the first psychological support after the July 7 rally. |
| Moving-average support | $94 to $95 | The 50-day moving average near $94.44 is the first trend support to watch on a pullback. |
| Major support | $81 to $82 | The 200-day moving average near $81.87 is the larger trend reference if the turnaround trade unwinds. |
| Near resistance | $106 to $108 | This range overlaps the 52-week high area near $106.15 and may require earnings confirmation to clear. |
| Upper resistance | $115 to $120 | This is a potential extension zone if Q2 results and 2026 guidance continue to improve. |
| Moving averages | 50-day near $94.44, 200-day near $81.87 | Price is above both averages, so trend remains positive while CVS holds above the 50-day reference. |
| Momentum | RSI near 64.20 | Momentum is positive but close enough to overbought territory that failed breakouts deserve attention. |
| Volume | 20-day average near 7.99 million shares | Volume confirmation matters because health care policy headlines and earnings guidance can reverse the move. |
| Volatility | Watch Aug. 5, 2026 earnings | Q2 results, medical benefit ratio commentary, PBM headlines, and guidance updates are likely volatility catalysts. |
| Invalidation | Close below $94, then below $82 | A sustained break below the 50-day average would weaken the short-term setup. A break below the 200-day average would challenge the broader recovery thesis. |
CVS AI trading strategy
The CVS AI trading strategy below is a rules-based research framework, not personal advice. It links the stock chart with Aetna margin recovery, Caremark PBM durability, pharmacy reimbursement pressure, cash flow, debt, dividends, and management guidance.
Watch for CVS to hold above the $94 to $95 50-day moving-average zone and break above $106 to $108 with Q2 results confirming adjusted EPS guidance, medical cost discipline, and cash flow strength.
A failed breakout followed by a close below $94 should reduce trend confidence, especially if management points to higher medical costs, weaker PBM economics, or pharmacy margin pressure.
If CVS pulls back toward $82 to $90 without a cut to 2026 guidance or deterioration in operating cash flow, compare the lower price with the base-case recovery range and dividend coverage.
Do not treat a lower price as attractive if GAAP earnings remain impaired by new charges, debt reduction stalls, or Aetna margins fail to improve.
Track Health Care Benefits medical benefit ratio, Caremark client retention, pharmacy reimbursement pressure, Oak Street clinic decisions, adjusted EPS guidance, operating cash flow, debt, dividend coverage, and PBM policy proposals.
Position sizing should reflect that CVS is a regulated health care turnaround, not a guaranteed defensive compounder.
Investment research summary
Customers pay CVS to make health care access, prescriptions, benefits, insurance, and care coordination more convenient and affordable. The company monetizes pharmacy traffic, prescription volume, PBM scale, insurance premiums, and care delivery relationships.
The moat comes from national retail pharmacy presence, Caremark scale, Aetna membership, claims data, specialty pharmacy, employer and plan relationships, and integrated benefit design. The moat is not absolute because regulators and large customers can pressure PBM economics and reimbursement terms.
The thesis fails if medical costs exceed pricing, Medicare Advantage margins stay weak, PBM reform removes economics, pharmacy reimbursement pressure accelerates, care delivery assets require more charges, or debt limits strategic flexibility.
David Joyner is trying to rebuild credibility through margin recovery, cash flow discipline, store optimization, and tighter care delivery decisions. The proof point is whether improved adjusted earnings show up in cleaner GAAP earnings and lower balance-sheet risk.
CVS sits inside a long-term U.S. health care affordability problem where payers, employers, pharmacies, and patients need lower friction and better coordination. That supports demand, but the same affordability pressure creates regulation, litigation, and pricing risk.
At $104.33, CVS is no longer priced like a broken story. Margin of safety depends on whether adjusted EPS near $7.30 to $7.50 becomes durable cash earnings and whether debt, medical costs, and PBM pressure stop absorbing the recovery.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CVS quote reference | $104.33 close on July 7, 2026, and $103.93 pre-market reference | StockAnalysis CVS overview | July 8, 2026 |
| Market capitalization verification | $133.12 billion reported and $133.21 billion calculated from $104.33 x 1.27686 billion shares | Pineify financial_rigor.py and StockAnalysis CVS overview | July 8, 2026 |
| Shares outstanding | 1.28 billion shares outstanding, rounded market-data figure | StockAnalysis CVS overview | July 8, 2026 |
| FY2025 revenue | $402.07 billion total revenues in the FY2025 company release, cross-checked against the 2025 Annual Report and StockAnalysis TTM revenue of $405.62 billion | CVS Health FY2025 results release | July 8, 2026 |
| FY2025 net income | $1.77 billion net income attributable to CVS Health in the 2025 Annual Report, with StockAnalysis TTM net income at $2.93 billion due to newer trailing-period timing | CVS Health 2025 Annual Report | July 8, 2026 |
| Q1 2026 results and guidance | $100.4 billion Q1 revenue, $2.30 GAAP EPS, $2.57 adjusted EPS, and raised 2026 adjusted EPS guidance of $7.30 to $7.50 | CVS Health Q1 2026 results release | July 8, 2026 |
| Cash and debt | $8.45 billion cash and cash equivalents at Dec. 31, 2025 in the Annual Report; StockAnalysis later TTM balance sheet showed $11.80 billion cash and $78.35 billion debt | CVS Health 2025 Annual Report and StockAnalysis statistics | July 8, 2026 |
| Valuation ratios | 45.36x TTM EPS, 1.71x book value, 17.99x free cash flow per share, 2.55% dividend yield, and 13.68x forward PE | Pineify financial_rigor.py and StockAnalysis CVS statistics | July 8, 2026 |
| Technical indicators | 50-day moving average $94.44, 200-day moving average $81.87, RSI 64.20, 20-day average volume 7.99 million, and 52-week range $58.50 to $106.15 | StockAnalysis CVS overview and statistics | July 8, 2026 |
This CVS AI stock analysis is an informational research tool only and is not investment advice, tax advice, or a recommendation to buy or sell CVS Health Corporation shares. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, medical costs, regulation, debt, interest rates, or market conditions change.
